Alliance Foundation Trials and Natera announce AFT-70 NAVIGATE, a global Phase III breast cancer trial
NTRA•Alliance Foundation Trials and Natera announced AFT-70 NAVIGATE, a global, randomized Phase III trial evaluating Genentech’s oral selective estrogen receptor degrader with Signatera MRD-guided CDK4/6 inhibitor therapy in breast cancer.
1. Trial announcement
Alliance Foundation Trials and Natera announced AFT-70 NAVIGATE, a global, randomized Phase III trial evaluating Genentech’s oral selective estrogen receptor degrader with Signatera MRD-guided CDK4/6 inhibitor therapy in breast cancer.
